New Data at American College of Gastroenterology Annual Meeting Show TissueCypher® Provides ...

BRIEF-Castle Biosciences Inc Says Tissuecypher® Provides Actionable Risk Insights That Influence Clinical Management And Prompt Risk-Aligned Intervention In Barrett’s Esophagus

Oct 26 (Reuters) – Castle Biosciences Inc: * NEW DATA AT AMERICAN COLLEGE OF GASTROENTEROLOGY ANNUAL MEETING SHOW TISSUECYPHER® PROVIDES ACTIONABLE RISK INSIGHTS THAT INFLUENCE CLINICAL MANAGEMENT AND PROMPT RISK-ALIGNED INTERVENTION IN BARRETT’S ESOPHAGUS * CASTLE BIOSCIENCES INC – TISSUECYPHER SHOWS 34% AND 62% FIVE-YEAR PROGRESSION RISK Source text: Further company coverage: (The article has been published through a syndicated feed. Except fo…

New Data at American College of Gastroenterology Annual Meeting Show TissueCypher® Provides ...

FRIENDSWOOD, Texas, Oct. 26, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data demonstrating that its TissueCypher® Barrett’s Esophagus test can provide risk insights beyond…

New Data at American College of Gastroenterology Annual Meeting Show TissueCypher® Provides Actionable Risk Insights that Influence Clinical Management and Prompt Risk-Aligned Intervention in Barrett’s Esophagus

Castle Biosciences (Nasdaq: CSTL) presented new data at ACG 2025 showing the TissueCypher test provides risk insights beyond pathology and influenced clinical management in multiple Barrett’s esophagus cohorts.Key highlights: TissueCypher returned five-year progression probabilities of 34%, 62%, 43% and 45% in case studies, exceeded published HGD→EAC five-year rate of 33%, and influenced management in 93% of 114 rural NDBE patients; three poster…